Cohen, Romain

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

Fucà, G., Cohen, R., Lonardi, S., Shitara, K., Elez, M. E., Fakih, M., Chao, J., Klempner, S. J., Emmett, M., Jayachandran, P., et al. (2022) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersIntraperitoneal and Appendiceal Malignancies

Cited by 129

MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors

Svrcek, M., Lascols, O., Cohen, R., Collura, A., Jonchère, V., Fléjou, J.-F., Buhard, O., & Duval, A. (2019) · Bulletin du Cancer

Genetic factors in colorectal cancerCancer Immunotherapy and Biomarkers

Cited by 90

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency

Cohen, R., Colle, R., Pudlarz, T., Heran, M., Duval, A., Svrcek, M., & André, T. (2021) · Cancers

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 47

Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial

Ghiringhelli, F., Chibaudel, B., Taieb, J., Bennouna, J., Martin-Babau, J., Fonck, M., Borg, C., Cohen, R., Thibaudin, M., Limagne, E., et al. (2020) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 40